Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer

BACKGROUND: We studied the utility of the tumor suppressor Tristetraprolin (TTP, ZFP36) as a clinically relevant biomarker of aggressive disease in prostate cancer patients after radical prostatectomy (RP). METHODS: TTP RNA expression was measured in an RP cohort of patients treated at Moffitt Cance...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Epidemiol Biomarkers Prev
Autors principals: Rounbehler, Robert J., Berglund, Anders E., Gerke, Travis, Takhar, Mandeep M., Awasthi, Shivanshu, Li, Weimin, Davicioni, Elai, Erho, Nicholas G., Ross, Ashley E., Schaeffer, Edward M., Klein, Eric A., Karnes, R. Jeffrey, Jenkins, Robert B., Cleveland, John L., Park, Jong Y., Yamoah, Kosj
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214732/
https://ncbi.nlm.nih.gov/pubmed/30108099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-18-0369
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars